Cargando…

Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial

Intraoperative remifentanil infusion may paradoxically induce post-surgical hyperalgesia. Dexmedetomidine reportedly reduces opioid-induced hyperalgesia. Nalmefene selectively reverses several side-effects of opioids without impairing analgesia. Herein, this randomized, double-blind controlled trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Zhen, Chen, Yi, Gao, Tianyu, Yuan, Yuan, Zheng, Yuxin, Xie, Yegong, Wang, Guolin, Yu, Yonghao, Zhang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905252/
https://www.ncbi.nlm.nih.gov/pubmed/36762101
http://dx.doi.org/10.3389/fphar.2023.1131812
_version_ 1784883791555198976
author Jia, Zhen
Chen, Yi
Gao, Tianyu
Yuan, Yuan
Zheng, Yuxin
Xie, Yegong
Wang, Guolin
Yu, Yonghao
Zhang, Linlin
author_facet Jia, Zhen
Chen, Yi
Gao, Tianyu
Yuan, Yuan
Zheng, Yuxin
Xie, Yegong
Wang, Guolin
Yu, Yonghao
Zhang, Linlin
author_sort Jia, Zhen
collection PubMed
description Intraoperative remifentanil infusion may paradoxically induce post-surgical hyperalgesia. Dexmedetomidine reportedly reduces opioid-induced hyperalgesia. Nalmefene selectively reverses several side-effects of opioids without impairing analgesia. Herein, this randomized, double-blind controlled trial investigated whether nalmefene, dexmedetomidine, and both drugs combined prevent remifentanil-induced hyperalgesia. One hundred and fifty patients undergoing elective laparoscopic gynecological surgery under desflurane anesthesia randomly received either intraoperative sufentanil 0.20 μg kg(−1) (Group S), or remifentanil 0.20 μg kg(−1) min(−1) (Group R), or remifentanil and pre-anesthesia nalmefene 0.20 μg kg(−1) (Group N), or remifentanil and pre-anesthesia dexmedetomidine 0.50 μg kg(−1) (Group D), or remifentanil and the combination of dexmedetomidine 0.25 μg kg(−1) and nalmefene 0.10 μg kg(−1) (Group DN). The threshold of postoperative mechanical hyperalgesia (primary outcome) was measured with von Frey filaments. We also recorded pain intensity, analgesic consumptions, hyperalgesic area, and side-effects for 24 h postoperatively. Compared with Group S, remifentanil reduced hyperalgesic threshold on the forearm [mean 89.4 (SD 13.7) vs. 62.2 (10.7) g, p < 0.001] at postoperative 24 h. Pain threshold on the forearm at postoperative 24 h was significantly lower in Group R than in Groups N, D and DN [62.2 (10.7) vs. 71.1 (12.3), 72.4 (12.9) and 78.0 (13.8) g]. Compared with Group R, Postoperative pain intensity, analgesic consumption and hyperalgesic area were lower likewise in Groups D and DN. However, the incidence of intraoperative bradycardia was lower and post-anesthesia recovery time was shorter in Group DN than Group D. Preoperative therapy of dexmedetomidine and nalmefene combined attenuates postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery under desflurane-remifentanil anesthesia.
format Online
Article
Text
id pubmed-9905252
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99052522023-02-08 Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial Jia, Zhen Chen, Yi Gao, Tianyu Yuan, Yuan Zheng, Yuxin Xie, Yegong Wang, Guolin Yu, Yonghao Zhang, Linlin Front Pharmacol Pharmacology Intraoperative remifentanil infusion may paradoxically induce post-surgical hyperalgesia. Dexmedetomidine reportedly reduces opioid-induced hyperalgesia. Nalmefene selectively reverses several side-effects of opioids without impairing analgesia. Herein, this randomized, double-blind controlled trial investigated whether nalmefene, dexmedetomidine, and both drugs combined prevent remifentanil-induced hyperalgesia. One hundred and fifty patients undergoing elective laparoscopic gynecological surgery under desflurane anesthesia randomly received either intraoperative sufentanil 0.20 μg kg(−1) (Group S), or remifentanil 0.20 μg kg(−1) min(−1) (Group R), or remifentanil and pre-anesthesia nalmefene 0.20 μg kg(−1) (Group N), or remifentanil and pre-anesthesia dexmedetomidine 0.50 μg kg(−1) (Group D), or remifentanil and the combination of dexmedetomidine 0.25 μg kg(−1) and nalmefene 0.10 μg kg(−1) (Group DN). The threshold of postoperative mechanical hyperalgesia (primary outcome) was measured with von Frey filaments. We also recorded pain intensity, analgesic consumptions, hyperalgesic area, and side-effects for 24 h postoperatively. Compared with Group S, remifentanil reduced hyperalgesic threshold on the forearm [mean 89.4 (SD 13.7) vs. 62.2 (10.7) g, p < 0.001] at postoperative 24 h. Pain threshold on the forearm at postoperative 24 h was significantly lower in Group R than in Groups N, D and DN [62.2 (10.7) vs. 71.1 (12.3), 72.4 (12.9) and 78.0 (13.8) g]. Compared with Group R, Postoperative pain intensity, analgesic consumption and hyperalgesic area were lower likewise in Groups D and DN. However, the incidence of intraoperative bradycardia was lower and post-anesthesia recovery time was shorter in Group DN than Group D. Preoperative therapy of dexmedetomidine and nalmefene combined attenuates postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery under desflurane-remifentanil anesthesia. Frontiers Media S.A. 2023-01-25 /pmc/articles/PMC9905252/ /pubmed/36762101 http://dx.doi.org/10.3389/fphar.2023.1131812 Text en Copyright © 2023 Jia, Chen, Gao, Yuan, Zheng, Xie, Wang, Yu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jia, Zhen
Chen, Yi
Gao, Tianyu
Yuan, Yuan
Zheng, Yuxin
Xie, Yegong
Wang, Guolin
Yu, Yonghao
Zhang, Linlin
Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
title Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
title_full Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
title_fullStr Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
title_full_unstemmed Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
title_short Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
title_sort nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: a randomized double-blind controlled trial
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905252/
https://www.ncbi.nlm.nih.gov/pubmed/36762101
http://dx.doi.org/10.3389/fphar.2023.1131812
work_keys_str_mv AT jiazhen nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT chenyi nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT gaotianyu nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT yuanyuan nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT zhengyuxin nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT xieyegong nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT wangguolin nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT yuyonghao nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial
AT zhanglinlin nalmefenevsdexmedetomidineforpreventionofpostoperativehyperalgesiainpatientsundergoinglaparoscopicgynecologicalsurgerywithremifentanilinfusionarandomizeddoubleblindcontrolledtrial